Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

505419 α,β-methylene ATP - CAS 104809-20-3 - Calbiochem

α,β-methylene ATP - CAS 104809-20-3 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: αβ-MeATP, αβ-methylene ATP, P2X purinergic receptor agonist, α,β-methylene ATP, α,β-Methyleneadenosine 5ʹ-triphosphate lithium salt

Primary Target: P2X
505419
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
104809-20-3C₁₁H₁₈N₅O₁₂P₃ • xLi+

Products

Catalogue NumberPackaging Qty/Pack
5.05419.0001 Sklená flaša 5 mg
Description
OverviewA metabolically stable and selective P2X purinergic receptor agonist (pEC50 = 5.81) that is shown to be more potent than ATP. Elicits contractions in ileum through the release of endogenous acetylcholine, which can be blocked by tetrodotoxin (~1 mM). Shown to depolarize cells of the longitudinal muscle strips (~ 200 nM to 4 µM) that reaches a peak within 2-3 min after application and then decays to a steady level.
Catalogue Number505419
Brand Family Calbiochem®
Synonymsαβ-MeATP, αβ-methylene ATP, P2X purinergic receptor agonist, α,β-methylene ATP, α,β-Methyleneadenosine 5ʹ-triphosphate lithium salt
References
ReferencesSawyer, G.W., et al. 2000. Br. J. Pharmacol. 129, 1458.
Komori, S., et al. 1988. Br. J. Pharmacol. 94, 9.
Product Information
CAS number104809-20-3
FormWhite powder
Hill FormulaC₁₁H₁₈N₅O₁₂P₃ • xLi+
Chemical formulaC₁₁H₁₈N₅O₁₂P₃ • xLi+
Hygroscopic Hygroscopic
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetP2X
Purity≥93% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
5.05419.0001 04055977243833

Documentation

α,β-methylene ATP - CAS 104809-20-3 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Sawyer, G.W., et al. 2000. Br. J. Pharmacol. 129, 1458.
Komori, S., et al. 1988. Br. J. Pharmacol. 94, 9.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision30-October-2023 JSW
Synonymsαβ-MeATP, αβ-methylene ATP, P2X purinergic receptor agonist, α,β-methylene ATP, α,β-Methyleneadenosine 5ʹ-triphosphate lithium salt
DescriptionA metabolically stable and selective P2X purinergic receptor agonist (pEC50 = 5.81) that is shown to be more potent than ATP. Elicits contractions in ileum through the release of endogenous acetylcholine, which can be blocked by tetrodotoxin (~1 mM). Shown to depolarize cells of the longitudinal muscle strips (~ 200 nM to 4 µM) that reaches a peak within 2-3 min after application and then decays to a steady level.
FormWhite powder
CAS number104809-20-3
Chemical formulaC₁₁H₁₈N₅O₁₂P₃ • xLi+
Structure formulaStructure formula
Purity≥93% by HPLC
SolubilityH₂O (100 mg/ml)
Storage Protect from light
-20°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesSawyer, G.W., et al. 2000. Br. J. Pharmacol. 129, 1458.
Komori, S., et al. 1988. Br. J. Pharmacol. 94, 9.